Former Operator Warp Speed chief adviser addresses Biden administration to get credit for distributing coronavirus vaccines.
A laboratory study suggests that the South African variant of the coronavirus could reduce antibody protection against the Pfizer Inc / BioNTech SE vaccine by two-thirds, and it is not clear whether the shot is effective against the mutation, the companies said on Wednesday. said.
The study found that the vaccine was still able to neutralize the virus, and there is still no evidence from trials in humans that the variant reduces the protection of the vaccine, the companies said.
US BUYS 100 M MORE COVID VACCINE DOSES FROM PFIZER
Yet they make investments and talk to regulators about developing an updated version of their mRNA vaccine or an enhancer shot, if necessary.
For the study, scientists from the companies and the University of Texas Medical Branch (UTMB) developed a engineered virus that contained the same mutations found at the peak portion of the highly contagious coronavirus variant first discovered in South Africa, known as B .1.351, contains. The peak, which is used by the virus to enter human cells, is the primary target of many vaccines.
| Ticker | Safety | Last | Alter | Alter% |
|---|---|---|---|---|
| PFE | PFIZER INC. | 34.88 | +0.20 | + 0.58% |
Researchers tested the engineered virus against blood taken from people who received the vaccine, and found a two-thirds reduction in the level of neutralizing antibodies compared to the effect on the most common version of the virus found in the US. trials occur.
Their findings were published in the New England Journal of Medicine (NEJM).
GET FOX-BUSINESS PARTS BY CLICK HERE
Because there is no standard yet to determine which antibodies are needed to protect against the virus, it is unclear whether reducing two-thirds will make the vaccine ineffective against the variant that is spreading around the world.
However, UTMB professor and co-author of the study, Pei-Yong Shi, said he believes the Pfizer vaccine is likely to be protective against the variant.
‘We do not know what the minimum neutralizing number is. We do not have the cut-off point, ”he said, adding that he suspected that the observed immune response was likely to be significantly higher than it should be to provide protection.
CLICK HERE TO READ MORE ABOUT FOX BUSINESS
This is because both the Pfizer / BioNTech vaccine and a similar uptake of Moderna Inc in clinical trials provide some protection after a single dose with an antibody response lower than the reduced levels shown by the South African variant in the laboratory study. caused.
Even if the variant in question significantly reduces its effectiveness, the vaccine should still protect against serious diseases and death, he noted. Health experts said it was the most important factor in preventing protracted healthcare systems from being overwhelmed.